TL;DR
This study identifies a specific gene expression signature that correlates with vaccine-induced protection against HIV-1. This signature is linked to antibody-dependent cellular phagocytosis (ADCP), primarily driven by monocytes, suggesting a key mechanism for vaccine efficacy and offering a potential tool for screening future vaccine candidates.
What Problem Does This Paper Address?
Developing an effective HIV vaccine has been a major challenge. While some vaccine trials have shown partial protection, the underlying mechanisms are not fully understood. Previous research identified a gene signature in non-human primates (NHPs) that correlated with protection against SIV/SHIV. This study aims to validate this signature in human trials, investigate its association with antibody-dependent cellular phagocytosis (ADCP), and pinpoint the cellular origins of this protective signature to better understand and potentially improve vaccine design.
Methods
The researchers employed several advanced techniques:
- Bulk Transcriptomics (RNA-seq): Used to analyze gene expression in peripheral blood mononuclear cells (PBMCs) from participants in HIV vaccine trials (RV306 and HVTN 505).
- Single-cell Transcriptomics (CITE-seq): A novel approach that simultaneously measures mRNA and cell surface protein expression from individual cells. This allowed them to identify which specific cell types were expressing the protective gene signature.
- Gene Set Enrichment Analysis (GSEA): Used to determine if the identified gene signature was enriched in participants with specific outcomes (e.g., protection vs. infection, high vs. low ADCP).
- Composite Gene Expression Score (GES): A computational score derived from the average standardized expression of genes within the signature, used to assess its correlation with protection and other immune responses.
- Pathway Analysis (GeneMANIA, Metascape): To understand the biological functions and pathways associated with the genes in the protective signature.
Datasets
The study utilized data from several human and NHP HIV vaccine trials:
- RV306 trial: An immunogenicity trial using the RV144 vaccine regimen. Data from this trial was used for transcriptomic analysis (RNA-seq and CITE-seq) and ADCP measurements.
- HVTN 505 trial: A human efficacy trial of a DNA/rAd5 vaccine that did not show overall efficacy. This was used to test the specificity of the gene signature for protective vaccines.
- NHP studies: Previously published data from NHP challenge studies using Ad26 and ALVAC/gp120 vaccines were used for initial validation and correlation analyses.
- RV144 trial: Previously published microarray data was used for correlates of protection analysis.
Key Insights and Ideas
- Specificity of the Signature: The protective gene signature was absent in a failed HIV vaccine trial (HVTN 505), strongly suggesting it's a marker of effective vaccine-induced protection, not just a general response to vaccination.
- ADCP as a Mechanism: The study provides compelling evidence that antibody-dependent cellular phagocytosis (ADCP) is a key mechanism underlying vaccine-induced protection, mediated by the identified gene signature.
- Monocytes are Key Players: Single-cell analysis revealed that the protective genes are predominantly expressed in myeloid cells, particularly monocytes, which are known to be crucial for ADCP.
- GES as a Predictive Tool: The composite Gene Expression Score (GES) derived from the signature proved to be a robust correlate of reduced HIV-1 infection risk and increased vaccine efficacy, even outperforming traditional correlates like V1V2 IgG antibodies in the RV144 trial.
- Early Detection Potential: The association of the gene signature with ADCP responses as early as 3 days post-vaccination suggests that this signature could be used to assess vaccine response early in clinical trials.
Key Results
- The gene signature was significantly enriched in the partially protective RV144 trial and associated with decreased HIV-1 acquisition risk and increased vaccine efficacy (VE).
- In the RV306 trial, the gene signature strongly correlated with higher magnitudes of ADCP responses.
- CITE-seq analysis showed that genes in the signature were primarily expressed in monocytes, which are key effector cells for ADCP.
- The GES derived from the RV144 signature was a stronger correlate of reduced HIV-1 infection risk than V1V2-specific IgG antibodies.
- The GES was able to predict HIV-1 infection with an AUC of 0.67±0.08 and accuracy of 0.81±0.04 in the RV144 trial.
Limitations and Future Work
- Cellular Origin Nuance: While monocytes were identified as the primary source of the signature, the authors acknowledge that the signature might represent a broader biological state rather than being strictly confined to a single cell type. Granulocytes (like neutrophils) might also play a role, but their contribution is missed in PBMC analysis.
- Generalizability: The study emphasizes the need for replication of findings across multiple studies to strengthen the credibility of the gene signature as a correlate of protection.
- Future Directions: The authors propose that this gene signature can serve as a valuable tool for:
- Identifying potential mechanisms of vaccine protection (like ADCP).
- Screening novel vaccine candidates to accelerate development.
- Providing orthogonal insights for down-selecting vaccine candidates in human immunogenicity trials.
- Facilitating meta-analyses of data from ongoing and past HIV vaccine trials.
Summary updated